Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Autolus Therapeutics Plc ADR
(NQ:
AUTL
)
3.865
+0.025 (+0.65%)
Streaming Delayed Price
Updated: 10:06 AM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Autolus Therapeutics Plc ADR
< Previous
1
2
3
4
5
6
Next >
Autolus Therapeutics announces publication in ACS Chemical Biology
January 23, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
January 22, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Chart Of The Day: Autolus Therapeutics - Effective Cancer Treatments
January 12, 2024
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer.
Via
Talk Markets
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
January 10, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Analyst Expectations for Autolus Therapeutics's Future
December 13, 2023
Via
Benzinga
Autolus Therapeutics PLC (NASDAQ: AUTL) Climbs to New 52-Week High
November 20, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 27, 2023
Via
Benzinga
Autolus Therapeutics Announces Changes to its Board of Directors
December 22, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
December 09, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 28, 2023
Via
Benzinga
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
November 27, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 15, 2023
Via
Benzinga
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
November 15, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces participation in upcoming conferences
November 06, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
November 02, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 02, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
October 17, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
October 11, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
October 11, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
September 05, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia
August 17, 2023
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9
Via
Benzinga
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
August 03, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
July 19, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
July 18, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
July 06, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces publication in Cancer Immunology Research
June 27, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director
June 20, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
June 16, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
3 Top Penny Stock Picks You Haven’t Heard Of
June 14, 2023
Here are three penny stock picks investors likely haven't heard of, but probably should keep on the radar as speculative options.
Via
InvestorPlace
Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023
June 06, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.